daunorubicin has been researched along with Chromosome Inversion in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Houssou, B; Lamchahab, M; Massi, R; Oukkache, B; Quessar, A | 1 |
| Akasaka, T; Honjo, G; Izumi, K; Kishimori, C; Maesako, Y; Ohno, H; Okamori, S; Okumura, A; Takeoka, K | 1 |
| Arthur, DC; Bloomfield, CD; Byrd, JC; Carroll, AJ; Davey, FR; Dodge, RK; Edwards, CG; Feldman, EJ; Koduru, PR; Larson, RA; Mayer, RJ; Moore, JO; Mrózek, K; Patil, SR; Pettenati, MJ; Rao, KW; Schiffer, CA; Stone, RM; Watson, MS | 1 |
| Bruyere, H; Copland, M; Hogge, DE; Horsman, DE; Lavoie, JC; Le, A; Nantel, SH; Nevill, TJ; Seftel, MD; Shepherd, JD; Sutherland, HJ; Toze, CL | 1 |
| Auvrignon, A; Bastard, C; Blaise, D; Castaigne, S; Dastugue, N; Delaunay, J; Dombret, H; Fenaux, P; Fière, D; Harousseau, JL; Lamy, T; Leblanc, T; Leverger, G; Mugneret, F; Pigneux, A; Reiffers, J; Rigal-Huguet, F; Van den Akker, J; Vey, N; Witz, F | 1 |
| Brandalise, SR; Matsuda, EI; Nowill, AE; Oliveira, SN; Rodrigues, PC; Viana, MB; Yunes, JA | 1 |
| Fujisawa, S; Harano, H; Ishigatsubo, Y; Kanamori, H; Mohri, H; Motomura, S; Tanabe, J | 1 |
| Arber, D; Dagis, A; Forman, SJ; Margolin, KA; Nademanee, A; Niland, J; O'Donnell, MR; Parker, PM; Schmidt, GM; Slovak, ML; Smith, EP; Snyder, DS; Somlo, G; Stein, AS | 1 |
| Bernasconi, P; Boni, M; Castoldi, GL; Ciolli, S; Clavio, M; Cox, MC; Cuneo, A; Del Poeta, G; Dini, D; Falzetti, D; Fanin, R; Gobbi, M; Isidori, A; Leoni, F; Liso, V; Malagola, M; Mandelli, F; Martinelli, G; Mecucci, C; Petti, MC; Piccaluga, PP; Rondelli, R; Russo, D; Sessarego, M; Specchia, G; Testoni, N; Torelli, G; Tura, S; Visani, G | 1 |
| Aihara, M; Chiba, Y; Kawamura, S; Mikami, T; Takami, H; Tsushima, Y; Yoshida, Y; Yukita, T | 1 |
2 review(s) available for daunorubicin and Chromosome Inversion
| Article | Year |
|---|---|
Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Inversion; Chromosomes, Human, Pair 16; Clinical Trials as Topic; Cytarabine; Daunorubicin; Disease-Free Survival; Female; France; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Life Tables; Male; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2003 |
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Deletion; Chromosome Inversion; Chromosomes, Human; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hepatomegaly; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Remission Induction; Retrospective Studies; Splenomegaly; Survival Analysis; Translocation, Genetic; Treatment Outcome | 2001 |
1 trial(s) available for daunorubicin and Chromosome Inversion
| Article | Year |
|---|---|
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Inversion; Chromosomes, Human; Cytarabine; Daunorubicin; Disease-Free Survival; Follow-Up Studies; Humans; Incidence; Karyotyping; Leukemia, Myeloid; Life Tables; Prospective Studies; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Translocation, Genetic; Treatment Outcome; Trisomy | 2002 |
7 other study(ies) available for daunorubicin and Chromosome Inversion
| Article | Year |
|---|---|
Characteristics of adult patients treated for acute myeloid leukemia with inv 16 in Casablanca (Morocco).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Chromosome Inversion; Chromosomes, Human, Pair 16; Core Binding Factor beta Subunit; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukocytosis; Longitudinal Studies; Male; Middle Aged; Morocco; Myosin Heavy Chains; Oncogene Proteins, Fusion; Prognosis; Young Adult | 2018 |
inv(2)(p23q13)/RAN-binding protein 2 (RANBP2)-ALK fusion gene in myeloid leukemia that developed in an elderly woman.
Topics: Aged; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Inversion; Chromosomes, Human, Pair 2; Cytarabine; Daunorubicin; Diagnosis, Differential; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Molecular Chaperones; Nuclear Pore Complex Proteins; Oncogene Proteins, Fusion; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2014 |
Fulminant tumour lysis syndrome in acute myelogenous leukaemia with inv(16)(p13;q22).
Topics: Adolescent; Adult; Antineoplastic Agents; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Daunorubicin; Female; Genetic Predisposition to Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Tumor Lysis Syndrome | 2002 |
Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brazil; Child; Child, Preschool; Chromosome Inversion; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Gene Expression Regulation, Leukemic; Genes, Wilms Tumor; Humans; Infant; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Male; Neoplasm Proteins; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Translocation, Genetic; WT1 Proteins | 2007 |
Acute minimally differentiated myeloid leukemia (M0) with inv(3)(q21q26).
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Chromosome Inversion; Chromosomes, Human, Pair 3; Cytarabine; Daunorubicin; Fatal Outcome; Humans; Leukemia, Myeloid; Male; Middle Aged; Prednisolone | 1999 |
High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Diseases; Chromosome Aberrations; Chromosome Deletion; Chromosome Inversion; Chromosomes, Human; Chromosomes, Human, Pair 7; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Logistic Models; Male; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Sepsis; Translocation, Genetic; Treatment Outcome | 2000 |
[Acute myelomonocytic leukemia with inv (16) (p13 q22) disappeared abnormal karyotype during complete remission].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Daunorubicin; Humans; Injections, Spinal; Karyotyping; Leukemia, Myelomonocytic, Acute; Male; Mercaptopurine; Methotrexate; Prednisolone; Remission Induction | 1989 |